LOGIN  |  REGISTER
Cue Biopharma
Viking Therapeutics

VentriPoint Diagnostics Announces Date and Timing for Release of Q2 2023 Financial Results and Webinar

August 25, 2023 | Last Trade: C$0.14 0.00 0.00

Toronto, Ontario – The Newswire – August 25,  2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to announce that it will release its second-quarter financial results for 2023 on Tuesday, August 29, 2023, after close of market.  Ventripoint will host a webinar/conference call at 11:00 a.m. (EST) on Wednesday, September 6, 2023, to discuss its Q2 2023 financial results and to provide an update on sales and marketing activities.  Details of the webinar/conference call are as follows:

PARTICIPANT TELEPHONE NUMBERS

Participant Link: https://www.c-meeting.com/web3/joinTo/3WYDHYDEHKKUTR/-Ex5Yhj0J28VjV9fPfIbZw

Alternatively, if participant does not have Internet, please call:

Canada/US Toll Free: 1-844-763-8274

International Toll: +1-647-484-8814

Please dial in 5 – 10 minutes prior to the scheduled start time and simply ask to join the call.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.  Learn more:  www.ventripoint.com.

For further information, please contact:

Jonathan Robinson CFA

This email address is being protected from spambots. You need JavaScript enabled to view it.

(416) 669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

 

Recursion

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB